Belite Bio files 6-K on Q2 2025 update

Belite Bio, Inc. filed a Form 6-K to furnish a press release dated August 11, 2025, in which the company reported its second quarter 2025 financial results and provided a corporate update.

Rhea-AI Filing Summary

Belite Bio, Inc. filed a Form 6-K to furnish a press release dated August 11, 2025, in which the company reported its second quarter 2025 financial results and provided a corporate update. The press release is attached as Exhibit 99.1 and is incorporated by reference.

The 6-K also states that this report is deemed incorporated by reference into all of Belite Bio’s effective registration statements under the Securities Act of 1933 from the filing date, unless later superseded. The filing is signed by Chief Executive Officer and Chairman Yu-Hsin Lin.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Belite Bio (BLTE) disclose in this Form 6-K?

Belite Bio uses this Form 6-K to furnish a press release reporting its second quarter 2025 financial results and a corporate update. The press release is attached as Exhibit 99.1 and is incorporated into the filing by reference for securities law purposes.

How is the Belite Bio (BLTE) Q2 2025 information provided to investors?

The company provides its Q2 2025 financial results and corporate update through a press release dated August 11, 2025. That press release is attached to the Form 6-K as Exhibit 99.1 and forms part of the official SEC-submitted information package.

How does this Belite Bio (BLTE) 6-K affect existing registration statements?

The Form 6-K states it is deemed incorporated by reference into all effective registration statements Belite Bio has filed under the Securities Act of 1933. This means the Q2 2025 information becomes legally part of those registration documents unless later superseded.

Who signed the Belite Bio (BLTE) Form 6-K for Q2 2025?

The Form 6-K is signed on behalf of Belite Bio by Yu-Hsin Lin, who is identified as Chief Executive Officer and Chairman. This signature indicates the filing is authorized by the company’s senior leadership under Securities Exchange Act requirements.

What exhibit is attached to Belite Bio’s (BLTE) August 2025 Form 6-K?

The filing includes Exhibit 99.1, which is a press release titled “Belite Bio Reports Second Quarter 2025 Financial Results and Provides a Corporate Update.” This exhibit contains the detailed financial and corporate information referenced in the 6-K cover text.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/11/2025 - 06:02 AM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15b-16 OF

THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2025

Commission File Number: 001-41359

Belite Bio, Inc

(Exact name of registrant as specified in its charter)

Not Applicable

(Translation of Registrant´s name into English)

12750 High Bluff Drive Suite 475,

San Diego, CA 92130

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F x Form 40-F ¨

On August 11, 2025, Belite Bio, Inc issued a press release entitled “Belite Bio Reports Second Quarter 2025 Financial Results and Provides a Corporate Update.” A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

This Report on Form 6-K shall be deemed to be incorporated by reference into all effective registration statements filed by the registrant under the Securities Act of 1933 and shall be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

EXHIBIT INDEX

Exhibit 99.1 — Press Release

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Belite Bio, Inc
	By:	/s/ Yu-Hsin Lin
	Name:	Yu-Hsin Lin
	Title:	Chief Executive Officer and Chairman

Date: August 11, 2025